INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
Public company

DNLIDenali Therapeutics Inc.

CIK 0001714899

EDGAR filingsOpen in network
Disclosed transactions9
Buys / sells0 / 6
Max Insider Score36
Connections7with evidence

DNLI · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
32
CS
Chin Peter ScottChief Medical Officer
DNLIDenali Therapeutics Inc.
Open-market sale
SELL$37K
1,654 sh
Sep 4, 2026Sep 9, 2026
traded Sep 4, 2026
+5dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Chin Peter ScottChief Medical Officer · Sep 9, 2026
  • ← Insider ofevidence
    Thornberry NancyDirector · Sep 4, 2026
  • ← Lobbied forevidence
    MANATT, PHELPS, AND PHILLIPSLDA Q2Y 2026 second quarter · issues not listed · Aug 26, 2026
10
TN
Thornberry NancyDirector
DNLIDenali Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL
$15K
615 sh
Sep 2, 2026
Sep 4, 2026
traded Sep 2, 2026
+2d
SEC FORM 4

Evidence

21
TN
Thornberry NancyDirector
DNLIDenali Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$247K
10.8K sh
Sep 2, 2026Sep 4, 2026
traded Sep 2, 2026
+2dSEC FORM 4

Evidence

8
WJ
Watts Ryan J.Director, President and CEO
DNLIDenali Therapeutics Inc.
Gift
G—
32.2K sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

20
SO
Schuth Alexander O.COFO and Secretary
DNLIDenali Therapeutics Inc.
Open-market sale
SELL$72K
2,857 sh
Aug 11, 2026Aug 13, 2026
traded Aug 11, 2026
+2dSEC FORM 4

Evidence

36
WJ
Watts Ryan J.Director, President and CEO
DNLIDenali Therapeutics Inc.
Open-market sale
SELL$581K
35.2K sh
Jan 6, 2026Jan 8, 2026
traded Jan 6, 2026
+2dSEC FORM 4

Evidence

36
SO
Schuth Alexander O.COFO and Secretary
DNLIDenali Therapeutics Inc.
Open-market sale
SELL$284K
17.2K sh
Jan 6, 2026Jan 8, 2026
traded Jan 6, 2026
+2dSEC FORM 4

Evidence

9
VT
Van Hauwermeiren TimothyDirector
DNLIDenali Therapeutics Inc.
Grant or award
A—
31.9K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC FORM 4

Evidence

9
VT
Van Hauwermeiren TimothyDirector
DNLIDenali Therapeutics Inc.
Grant or award
A—
10.6K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Watts Ryan J.Director, President and CEO · Jan 8, 2026
  • ← Insider ofevidence
    Schuth Alexander O.COFO and Secretary · Jan 8, 2026
  • ← Insider ofevidence
    Van Hauwermeiren TimothyDirector · Nov 6, 2025

    • Lobbying

    $140K reported · de-duplicated
    2026 Q2 $70K via firms2026 Q1 $70K via firms
    • MANATT, PHELPS, AND PHILLIPS$70K2026 Q1 · posted Aug 26, 2026 · Health issues
    • MANATT, PHELPS, AND PHILLIPS$70K2026 Q2 · posted Aug 26, 2026 ·

    Connected PAC contributions

    FEC · direct to members

    No contributions from a PAC connected to this company.